Overview

A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
A Phase 1b study to evaluate the safety and tolerability of MB310 given to patients who have active mild-to-moderate ulcerative colitis.
Phase:
PHASE1
Details
Lead Sponsor:
Microbiotica Ltd
Treatments:
Vancomycin